TABLE 7.
Immunological parameters at different visits of the study.
| Parameters | Group | V1 | V2 | V3 | P-value* | |||
|
|
|
|
||||||
| Mean | SD | Mean | SD | Mean | SD | (visit*treatment interaction) | ||
| TNF (pg/ml) | Control | 2.5 | 3.3 | 2.3 | 2.5 | 4.7 | 2.6 | 0.450 |
| VitD | 5.2 | 4.7 | 4.9 | 6.2 | 4.9 | 3.6 | ||
| IL-6 (pg/ml) | Control | 8.4 | 0.9 | 8.5 | 0.9 | 9.5 | 3.7 | 0.296 |
| VitD | 9.5 | 4.0 | 11.3 | 6.0 | 8.3 | 0.6 | ||
| Phagocytosis of Granulocytes (%) | Control | 96.9 | 2.2 | 95.8 | 3.6 | 96.3 | 4.0 | 0.601 |
| VitD | 96.9 | 4.2 | 97.5 | 1.3 | 98.1 | 0.8 | ||
| Phagocytosis of Monocytes (%) | Control | 91.7 | 2.0 | 86.3 | 5.9 | 88.9 | 4.2 | 0.807 |
| VitD | 91.5 | 2.8 | 87.7 | 4.6 | 90.2 | 3.3 | ||
| CD3+CD4+ (% lym) | Control | 65.0 | 12.2 | 66.5 | 9.2 | 66.5 | 9.0 | 0.692 |
| VitD | 66.4 | 7.3 | 65.6 | 9.5 | 65.7 | 7.9 | ||
| CD3+CD8+ (% lym) | Control | 28.1 | 9.8 | 28.8 | 9.3 | 29.1 | 9.1 | 0.990 |
| VitD | 27.2 | 7.1 | 28.2 | 7.0 | 28.3 | 7.2 | ||
| CD4/CD8 | Control | 2.6 | 1.2 | 2.6 | 1.0 | 2.6 | 1.0 | 0.168 |
| VitD | 2.7 | 1.0 | 2.5 | 1.0 | 2.5 | 0.9 | ||
| CD56 (% lym) | Control | 8.6 | 4.5 | 9.6 | 3.2 | 10.9 | 2.5 | 0.212 |
| VitD | 6.6 | 2.6 | 8.2 | 4.3 | 7.2 | 3.4 | ||
| CD8+CD56+ (% CD3– lym) | Control | 10.2 | 6.4 | 12.7 | 5.7 | 12.5 | 5.1 | 0.524 |
| VitD | 9.4 | 5.2 | 12.3 | 6.3 | 9.9 | 5.0 | ||
| CD8–CD56+ (% CD3– lym) | Control | 14.2 | 8.4 | 16.1 | 6.0 | 19.6 | 8.1 | 0.212 |
| VitD | 11.5 | 5.9 | 13.9 | 6.9 | 13.2 | 8.0 | ||
*Two-way repeated measures ANOVA.
TNF, tumor necrosis factor; IL, interleukin; lym, lymphocytes; VitD, vitamin D.